Abstract
Conclusions In this double-blind, randomized study extended-release venlafaxine 150 mg/day found to be effective in chronic migraine. Our study showed a clear effect that was in subgroup of subjects with medication overuse. In addition, in this study, the low number of adverse events showed venlafaxine to be well tolerated. Future controlled trials expended lon ger with larger sample size, should also support the effectiveness and safety of venlafaxine in patients suffering from chronic migraine. No conflict of interest.
Highlights
Chronic migraine (CM) is a disabling neurological disorder that is defined in different ways
Chronic migraine was defined according to the criteria of the Headache Classification Committee of the International Headache Society (IHS)
There was no statistically significant difference in terms of primary or secondary efficacy measures between topiramate-group and venlafaxine-group during the double-blind period. In this double-blind, randomized study extended-release venlafaxine 150 mg/day found to be effective in chronic migraine
Summary
Chronic migraine (CM) is a disabling neurological disorder that is defined in different ways. Efficacy and safety of venlafaxine for the treatment of chronic migraine: a randomized, double-blind, controlled trial M Togha*, F Taghdiri, S Razeghi Jahromi From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014 Copenhagen, Denmark.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
